PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System...
-
Upload
gerald-williamson -
Category
Documents
-
view
220 -
download
1
Transcript of PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System...
![Page 1: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/1.jpg)
PHAR 751 Pharmacogenomics
Sarah Brown, Pharm.D.Pharmacy Practice Resident
Asante Health [email protected]
![Page 2: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/2.jpg)
PK: p-gp & sex, racial background
∆ Males
■ Females
○ African Americans
▼European Americans
No difference between groups
![Page 3: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/3.jpg)
Genotype vs. Phenotype: exon 26
180 mg fexofenadine po
MDR1 exon 26, C3435T□ CT■ CC○ TTP=0.036 CC vs. TT
![Page 4: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/4.jpg)
Genotype vs. Phenotype: exon 21
MDR1 exon 21, G2677T□ GT■ GG○ TTP= 0.054 GG vs. TT
![Page 5: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/5.jpg)
Genotype vs. Phenotype
MDR1*1 or MDR1*2 alleles□ *1*2■ *1*1○ *2*2
![Page 6: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/6.jpg)
Study conclusions
• Multiple SNPs present in the human MDR1 gene
• Polymorphism alters p-gp activity
• Genetic variation differs d/t racial background
![Page 7: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/7.jpg)
Another Fexofenadine, p-gp study
• Is the disposition of fexofenadine in humans affected by polymorphisms of MDR1?
• TT genotype vs. CC genotype
Drescher, et al. MDR1 gene polymorphisms and disposition of the p-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-534.
![Page 8: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/8.jpg)
Drescher, et al. MDR1 gene polymorphisms and disposition of the p-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-534.
Fexofenadine concentration vs. Time
CC vs. TT genotype
■ CC○ TT
![Page 9: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/9.jpg)
GG vs. TT phenotype
Fexofenadine concentration vs. Time
■ GG○ TT
Not significant
Drescher, et al. MDR1 gene polymorphisms and disposition of the p-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-534.
![Page 10: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/10.jpg)
Different conclusions?
• This study: NS difference in PK of fexofenadine
• Known: fexofenadine is a p-gp substrate
• Unknown: lack of association btwn PK and polymorphism
![Page 11: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/11.jpg)
Polymorphisms: Enzymes
• Frequently polymorphic
• Phenotypic consequence– Leads to inter-individual variability in drug
response?– Other factors: molecular basis, expression of
other drug-metabolizing enzymes, concurrent medications or illnesses
![Page 12: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/12.jpg)
Consequences of enzyme polymorphisms: Drug toxicities
• Thiopurine methyltransferase-deficiency– Hematopoietic toxicity when treated w/
standard doses of azathioprine or mercaptopurine
• Slow acetylator phenotype– Hydralazine-induced lupus– Isoniazid-induced neuropathies– Dye-associated bladder cancer– Sulfonamide-induced hypersensitivity rxns
![Page 13: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/13.jpg)
NAT2 polymorphism: Isoniazid
Slow acetylator vs. Fast acetylator
![Page 14: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/14.jpg)
N-acetyltransferase (NAT2) polymorphism
• Europe, North America: 40 – 70% slow acetylators (SA)
• Pacific Asian: 10 – 30% SA
• Egyptian and Moroccan: 80 – 90% SA
• Canadian Eskimo: 5% SA
![Page 15: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/15.jpg)
Agents Undergoing Polymorphic N-acetylation
• Acebutolol (a)• Isoniazid• Aminobenzoic Acid• Nitrazepama• Aminogluthethimide• Phenelzine• Aminosalicylic Acid• Procainamide• Amrinone
• Sulfadiazine• Caffeine (a)• Sulfamerazine• Clonazepam• Sulfamethazine• Dapsone• Sulfapyridine• Hydralazine• Sulfasalazine
(a) =Requires metabolism before N-acetylation
![Page 16: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/16.jpg)
CYP2C polymorphismsEnzyme Drug Interaction
CYP2C9 Warfarin
Glipizide
Tolbutamide
Phenytoin
↑ bleeding, ↑ incidence of severe bleeding in PMs
Possiblility of low BS in PMs
Signs of overdose; ataxia, disturbances of consciousness, mental confusion
CYP2C19 Diazepam
Omeprazole
Prolonged sedation in PMs, unconsciuosness (Asian population)
Reports of ↓ cure rates at low dosages in EMs
![Page 17: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/17.jpg)
Consequences of enzyme polymorphisms
• ↑ CYP1A activity + slow acetylation = ↓ myelosuppression from active metabolites of amonafide
• ↓ drug-metabolizing enzyme ↓ pro-drug activation– CYP2D6, opioid analgesics
![Page 18: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/18.jpg)
PK: Ethnic differences
• Unlikely:– No gut or hepatic first-pass effect– Low plasma protein-binding (<70-80%)– No/minimal hepatic metabolism– No/minimal renal tubular secretion
• Likely:– Gut or hepatic metabolism– High plasma protein-binding– Hepatic metabolism as major route
![Page 19: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/19.jpg)
Ethnic differences: hepatic metabolism
• Chinese vs. Caucasians
– Higher metabolism• Propranolol• Morphine
– No difference• Triazolam• Cerivastatin
– Lower metabolism• Desipramine• Alprazolam• Diazepam• Omeprazole• Nifedipine• Codeine
![Page 20: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/20.jpg)
Ethnic differences: hepatic metabolism
• African descent vs. Caucasians
– Higher metabolism• Propranolol
– Lower metabolism• Nifedipine• Methyprednisolone• Phenytoin
– No difference• Metoprolol/labetolol• Albuterol• Terbutaline• Trimazosin• Procainamide• Etoposide
![Page 21: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/21.jpg)
Ethnic variations
• Passive absorption, filtration at the glomerulus, and passive tubular reabsorption will not differ between ethnic groups
• For many drugs, PK prediction is difficult
![Page 22: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/22.jpg)
Genetic testing
• Carrier testing
• Diagnostic testing
• Newborn screening
• Pharmacogenetic testing
![Page 23: PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org.](https://reader036.fdocuments.net/reader036/viewer/2022062422/56649f2f5503460f94c48922/html5/thumbnails/23.jpg)
Clinical Relevance
• Small numbers of patients
• Availability of genotyping and phenotyping tools– Genetic testing– Predicting
• Drug interactions
• Therapeutic window
• In practice…